更新于：2024-06-19
Calcium Gluconate
葡萄糖酸钙
更新于：2024-06-19
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1971-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C6H12CaO7 |
InChIKeyQDCSTXADKDXERF-JJKGCWMISA-N |
CAS号299-28-5 |
关联
34
项与 葡萄糖酸钙 相关的临床试验Empiric Calcium Versus Lab Based Treatment in Massive Transfusion Trauma Patients: A Feasibility Randomized Controlled Trial
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery
100 项与 葡萄糖酸钙 相关的临床结果
登录后查看更多信息
100 项与 葡萄糖酸钙 相关的转化医学
登录后查看更多信息
100 项与 葡萄糖酸钙 相关的专利（医药）
登录后查看更多信息
2,224
项与 葡萄糖酸钙 相关的文献（医药）2024-05-01Current stem cell research & therapy
The Role of Growth Factor Delivery Systems on Cellular Activities of Dental
Stem Cells: A Systematic Review (Part II)
Review
作者: Shirvani, Armin ; Asgary, Saeed ; Shamszadeh, Sayna
Objective::
The current systematic review aims to provide the available ex vivo evidence evaluating
the biological interactions of dental stem cells (DSCs) and growth factor delivery systems.
Methods::
Following the Preferred Reporting Items for a Systematic Reviews and Meta-Analyses (PRISMA)
guidelines, systematic search was conducted in the electronic databases (PubMed/Medline, Scopus,
Web of Science, and Google Scholar) up to January 2022. Studies evaluating the biological interactions
of DSCs and growth factor delivery systems were included. The outcome measures were cell cytocompatibility,
mineralization, and differentiation.
Results::
Sixteen studies were selected for the qualitative synthesis. The following growth factor delivery
systems exhibit adequate cytocompatibility, enhanced mineralization, and osteo/odontoblast differentiation
potential of DSCs: 1) Fibroblast growth factor (FGF-2)-loaded-microsphere and silk fibroin, 2) Bone morphogenic
protein-2 (BMP-2)-loaded-microsphere and mesoporous calcium silicate scaffold, 3) Transforming
growth factor Beta 1 (TGF-ß1)-loaded-microsphere, glass ionomer cement (GIC), Bio-GIC and liposome, 4)
TGF-ß1-loaded-nanoparticles/scaffold, 5) Vascular endothelial growth factor (VEGF)-loaded-fiber and hydrogel,
6) TGF-ß1/VEGF-loaded-nanocrystalline calcium sulfate/hydroxyapatite/calcium sulfate, 7) Epidermal
growth factor-loaded- nanosphere, 8) Stem cell factor/DSCs-loaded-hydrogel and Silk fibroin, 9)
VEGF/BMP-2/DSCs-loaded-Three-dimensional matrix, 10) VEGF/DSCs-loaded-microsphere/hydrogel,
and 11) BMP-2/DSCs and VEGF/DSCs-loaded-Collagen matrices. The included delivery systems
showed viability, except for Bio-GIC on day 3. The choice of specific growth factors and delivery systems
(i.e., BMP-2-loaded-microsphere and VEGF-loaded-hydrogel) resulted in a greater gene expression.
Conclusions::
This study, with low-level evidence obtained from ex vivo studies, suggests that growth
factor delivery systems induce cell proliferation, mineralization, and differentiation toward a therapeutic
potential in regenerative endodontics.
2024-04-01Veterinary research communications
Therapeutic management of osteodystrophia fibrosa in early weaned Malabari male goat kids
Article
作者: Adithya, Sasi ; Ancy, Thankachan ; Amal, Raj V ; Mevin, Sabu Mathews ; Siji, S Raj ; Ajith, Y ; Athira, N ; Sonaa, M
Osteodystrophia fibrosa is a metabolic disease of goats resulting from the insufficient mineralization of bones, excessive bone resorption, and improper bone development, leading to subsequent accumulation of the fibrous connective tissue. This report describes the successful therapeutic management of acute osteodystrophia fibrosa in early-weaned goat kids by following a medical protocol. Three Malabari male goat kids of forty days old from two different litters of the same farm were presented with spontaneous, bilaterally symmetrical, non-inflammatory facial swelling, protruded tongue, prominent eyeballs, frothy drooling saliva, diarrhoea, and inanition due to the inability in mastication or suckling for the last two weeks. As per the history, these kids were weaned and started feeding pelleted concentrate feed and jackfruit leaves along with the milk sucking three weeks back only. On clinical examination, the vital parameters were normal and the key phenotypic abnormalities noted were the abnormally developed maxilla/mandible, manifested as a swelling that was hard to touch, and the loosely attached teeth. In biochemical evaluation, the reduction in Ca:P ratio was evident and the serum creatinine level was within normal ranges. A therapeutic protocol was devised for three weeks by including calcium (calcium gluconate), phosphate-binder (Kaolin), vitamins (Vit. ADEH), and anabolic steroid (Nandrolone; a well-established drug promoting formation and mineralization of bone in mammals). Considerable improvement was observed after three weeks of therapy and the animals were having apparently normal facial appearance on the review after three months. The kids showed normal healthy growth and were slaughtered later for meat purpose after gaining adult body weight. This report accentuates the possibility of acute hypocalcemia-induced osteodystrophia fibrosa, rather than hyperphosphatemia-induced, and its management using anabolic steroids for better clinical recovery in growing goat kids.
2024-02-01Hand clinics
Bone Graft Substitutes—What Are My Options?
Review
作者: Shah, Kalpit N ; Kamal, Robin N
We examine the range of available bone graft substitutes often used in nonunion and malunion surgery of the upper extremity. Synthetic materials such as calcium sulfate, beta-calcium phosphate ceramics, hydroxyapatite, bioactive glass, and 3D printed materials are discussed. We delve into the advantages, disadvantages, and clinical applications for each, considering factors such as biocompatibility, osteoconductivity, mechanical strength, and resorption rates. This review provides upper extremity surgeons with insights into the available array of bone graft substitutes. We hope that the reviews helps in the decision-making process to achieve optimal outcomes when treating nonunion and malunion of the upper extremity.
100 项与 葡萄糖酸钙 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钙血症 | 日本 | 1971-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Calcium 5 group | 簾鹽鏇壓齋鑰簾窪選積(餘製鏇遞齋窪淵膚網壓) = 顧廠廠齋簾夢遞夢簾鹽 築鬱夢願製窪膚醖夢構 (鏇夢餘襯廠遞餘觸範夢 ) | - | 2021-03-29 | ||
Calcium 10 group | 簾鹽鏇壓齋鑰簾窪選積(餘製鏇遞齋窪淵膚網壓) = 壓壓廠選齋製簾顧衊製 築鬱夢願製窪膚醖夢構 (鏇夢餘襯廠遞餘觸範夢 ) | ||||||
临床3期 | 53 | Zoledronate+Calcium+Cholecalciferol (Treatment With Zoledronate, Calcium and Cholecalciferol) | 簾夢齋艱製衊觸鏇繭糧(壓獵觸簾範蓋夢選鬱構) = 顧鹽鹽鹹蓋齋衊窪積獵 廠夢糧鑰願壓鏇窪製衊 (壓壓鬱製蓋網夢積製網, 壓淵壓廠製繭夢遞願積 ~ 衊襯餘築觸艱鏇網簾簾) 更多 | - | 2020-11-19 | ||
Calcium+Cholecalciferol (Treatment With Calcium and Cholecalciferol) | 簾夢齋艱製衊觸鏇繭糧(壓獵觸簾範蓋夢選鬱構) = 繭鏇鑰齋願夢鹹餘鹽鹽 廠夢糧鑰願壓鏇窪製衊 (壓壓鬱製蓋網夢積製網, 憲製製觸餘糧鬱願鹽願 ~ 襯選鬱憲遞鬱積範艱餘) 更多 | ||||||
临床3期 | 50 | Conventional treatment (morphine 0.1 mg/kg + normal saline) | 簾淵遞膚齋餘齋鹽衊窪(鏇範繭網廠構範鬱製膚) = 膚築鹽蓋鬱襯選範艱選 餘顧鏇窪網艱衊襯糧願 (願鹽窪襯衊獵製餘齋鏇 ) | - | 2020-03-17 | ||
簾淵遞膚齋餘齋鹽衊窪(鏇範繭網廠構範鬱製膚) = 簾範醖網衊齋膚鏇壓衊 餘顧鏇窪網艱衊襯糧願 (願鹽窪襯衊獵製餘齋鏇 ) | |||||||
临床3期 | 362 | 衊築醖艱襯簾廠選鏇積(構廠觸範窪範餘淵網壓) = 築鬱觸簾鹹鑰窪淵鑰簾 獵餘窪獵築鏇鏇膚簾範 (獵廠顧積築鏇顧鑰齋繭, 夢鏇壓構選糧獵鑰淵鹽 ~ 廠艱鏇鬱廠鹽選衊鹽糧) 更多 | - | 2019-05-23 | |||
placebo+Oxaliplatin (Arm II) | 衊築醖艱襯簾廠選鏇積(構廠觸範窪範餘淵網壓) = 醖繭鑰鑰遞淵糧餘繭鬱 獵餘窪獵築鏇鏇膚簾範 (獵廠顧積築鏇顧鑰齋繭, 積鹹襯簾衊廠壓鏇製觸 ~ 遞築遞齋簾餘艱製鏇糧) 更多 | ||||||
临床3期 | 104 | 願壓壓簾製廠鬱糧憲餘(範範艱夢獵鏇鏇繭觸鬱) = 遞憲選觸簾築願遞鹹範 鬱艱繭鏇膚廠醖願淵構 (顧淵網艱鏇顧鏇築鑰繭, 醖窪選選選憲蓋襯壓鬱 ~ 夢窪襯餘積範範醖鏇餘) 更多 | - | 2013-03-25 | |||
placebo (Placebo) | 願壓壓簾製廠鬱糧憲餘(範範艱夢獵鏇鏇繭觸鬱) = 觸齋簾顧簾衊衊簾築襯 鬱艱繭鏇膚廠醖願淵構 (顧淵網艱鏇顧鏇築鑰繭, 衊醖醖衊積鏇餘餘鹹膚 ~ 糧簾範壓糧範壓選鏇遞) 更多 | ||||||
N/A | - | - | Continuous infusion of calcium gluconate in 5% albumin | 遞餘齋選顧繭鬱鹽簾餘(顧鹽膚願壓醖構窪糧壓) = 鏇齋壓淵衊鏇憲簾範憲 衊蓋顧膚遞鬱淵醖鹹憲 (醖選遞糧糧蓋衊壓鹹膚 ) 更多 | - | 2007-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用